 |
 |
|
|
RESÚMENES JULIO 2007 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
Theory
of mind in schizophrenia. Meta-analysis
Mirjam Sprong, Patricia Schothorst, Ellen
Vos, Joop Hox, Herman Van Engeland
The British Journal of Psychiatry (2007) 191: 5-13
Cost-effectiveness
of first- v. second-generation
antipsychotic drugs: results from a randomised
controlled trial in schizophrenia responding poorly to previous therapy
L. M. Davies, S. Lewis, P. B. Jones, T. R. E. Barnes, F. Gaughran, K. Hayhurst, A. Markwick, H. Lloyd, the CUtLASS
team
The British Journal of Psychiatry (2007) 191: 14-22
Metabolic disease and
cardiovascular risk in people treated with antipsychotics
in the community
Paul Mackin, David Bishop, Helen Watkinson,
Peter Gallagher,
The British Journal of Psychiatry (2007) 191: 23-29
Antipsychotics
Sean D. Hood, Kenneth
G.D. Orr and David Nutt
Psychiatry. Volume 6, Issue 7, July
2007, Pages 295-300
TEXTO
GRATUITO
Efficacy and
Tolerability of Olanzapine, Quetiapine,
and Risperidone in the Treatment of Early Psychosis:
A Randomized, Double-Blind 52-Week Comparison
Joseph P. McEvoy, Jeffrey A. Lieberman, Diana
O. Perkins, Robert M. Hamer, Hongbin
Gu, Arthur Lazarus, Dennis Sweitzer,
Christina Olexy, Peter Weiden,
and Stephen D. Strakowski
Am J
Psychiatry 164:1050-1060, July 2007
Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive
Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Richard S.E. Keefe, John A. Sweeney, Hongbin Gu, Robert M. Hamer, Diana O.
Perkins, Joseph P. McEvoy, and Jeffrey A. Lieberman
Am J
Psychiatry 164:1061-1071, July 2007
Neural Synchrony in
Schizophrenia: From Networks to New Treatments
Judith M. Ford, John H. Krystal and Daniel H. Mathalon
Schizophrenia
Bulletin 2007 33(4):848-852
Biological, Life
Course, and Cross-Cultural Studies All point Toward the Value of Dimensional
and Developmental Ratings in the Classification of Psychosis
Rina Dutta, Talya Greene, Jean Addington, Kwame McKenzie,
Michael Phillips and Robin M. Murray
Schizophrenia
Bulletin 2007 33(4):868-876
The Neuropharmacology of Psychosis
Carol A. Tamminga and John M. Davis
Schizophrenia
Bulletin 2007 33(4):937-946
Persistent Negative
Symptoms in Schizophrenia: An Overview
Robert W. Buchanan
Schizophrenia
Bulletin 2007 33(4):1013-1022
Psychomotor Slowing
in Schizophrenia
Manuel Morrens, Wouter
Hulstijn and Bernard Sabbe
Schizophrenia
Bulletin 2007 33(4):1038-1053
A prospective study
of monitoring practices for metabolic disease in antipsychotic-treated
community psychiatric patients
Paul Mackin, David R Bishop and Helen MO Watkinson
BMC
Psychiatry
2007, 7:28
TEXTO GRATUITO
Perazine and Carbamazepine
in Comparison to Olanzapine in Schizophrenia
M.D. Ohlmeier, K. Jahn, C. Wilhelm-Gössling, T. Gödecke-Koch, J.
Hoffmann, J. Seifert, H.M. Emrich, U. Schneider
Neuropsychobiology 2007;55:81-88
Inflammation and schizophrenia
Xiaoduo Fan, Donald C Goff and David C Henderson
Expert Review of Neurotherapeutics. July 2007, Vol. 7, No. 7, Pages 789-796
Affect recognition deficits in
schizophrenia: neural substrates and psychopharmacological implications
Amy E Pinkham,
Raquel E Gur and Ruben C Gur
Expert Review of Neurotherapeutics. July 2007, Vol. 7, No. 7, Pages 807-816
Antipsychotic use
at adult ambulatory care visits by patients with mental health disorders in the
Jayashri Sankaranarayanan and Susan E. Puumala
Clinical
Therapeutics. Volume 29, Issue 4, April 2007, Pages 723-741
Risk of diabetic ketoacidosis
after exposure to risperidone or olanzapine
Ramaswamy K, Kozma CM, Nasrallah H
Ten-year
prospective follow-up study of the mortality by suicide in schizophrenic
patients
Frédéric Limosin, Jean-Yves Loze, Alain
Philippe, Françoise Casadebaig and Frédéric Rouillon
Schizophrenia
Research.
Volume 94, Issues 1-3, August 2007, Pages 23-28
Relation of
neurological soft signs to psychiatric symptoms in schizophrenia
Vijay A. Mittal, Wendy Hasenkamp, Michael Sanfilipo, Susan Wieland,
Schizophrenia
Research.
Volume 94, Issues 1-3, August 2007, Pages 37-44
Premorbid
behavioral and intellectual functioning in schizophrenia patients with poor
response to treatment with antipsychotic drugs
Asaf Caspi, Abraham Reichenberg, Mark
Weiser, Jonathan Rabinowitz, Motti
Shmushkevich, Gad Lubin, Daniella Nahon, Tali Vishne and Michael Davidson
Schizophrenia
Research.
Volume 94, Issues 1-3, August 2007, Pages 45-49
Neurological soft
signs and minor physical anomalies in patients with schizophrenia and related
disorders, their first-degree biological relatives, and non-psychiatric
controls
Michael T. Compton, Annie M. Bollini, LaTasha McKenzie Mack, Aimee D. Kryda,
Jessica Rutland, Paul S. Weiss, Zachary Bercu,
Michelle L. Esterberg and Elaine F. Walker
Schizophrenia
Research.
Volume 94, Issues 1-3, August 2007, Pages 64-73
The relationship
between symptomatic remission and neuropsychological improvement in
schizophrenia patients switched to treatment with ziprasidone
Peter F. Buckley,
Philip D. Harvey, Christopher R. Bowie and
Schizophrenia
Research.
Volume 94, Issues 1-3 August 2007, Pages 99-106
Effectiveness of
atypical antipsychotics for substance use in
schizophrenia patients
Jeffrey Swanson,
Richard A. Van Dorn and Marvin S. Swartz
Schizophrenia
Research.
Volume 94, Issues 1-3, August 2007, Pages 114-118
Sexual functioning,
psychopathology and quality of life in patients with schizophrenia
Xiaoduo Fan,
David C. Henderson, Elaine Chiang, Leah B. Namey
Briggs, Oliver Freudenreich, A. Eden Evins, Corinne Cather and Donald C. Goff
Schizophrenia
Research.
Volume 94, Issues 1-3, August 2007, Pages 119-127
Schizophrenic
patients treated with clozapine or olanzapine perform better on theory of mind tasks than
those treated with risperidone or typical
antipsychotic medications
Ioulia Savina and Richard J. Beninger
Schizophrenia
Research.
Volume 94, Issues 1-3, August 2007, Pages 128-138
Schizophrenia
Marco M Picchioni, Robin M Murray
TEXTO GRATUITO
Paliperidone extended release
Yang LP, Plosker GL
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an
acute episode of schizophrenia
Michael Riedel, Norbert Müller, Ilja Spellmann, Rolf R. Engel, Richard Musil, Rosamaria Valdevit, Sandra Dehning, Anette Douhet, Anja Cerovecki, Martin Strassnig and Hans-Jürgen Möller
European Archives of Psychiatry and Clinical
Neuroscience. Monday, July 16,
2007
Effects of risperidone and quetiapine
on cognition in patients with schizophrenia and predominantly negative symptoms
Michael Riedel,
Ilja Spellmann,
Martin Strassnig, Anette Douhet, Sandra Dehning,
Markus Opgen-Rhein, Rosamaria Valdevit, Rolf R. Engel, Nikolaus Kleindienst, Norbert Müller
and Hans-Jürgen Möller
European Archives of Psychiatry and Clinical Neuroscience. Monday, July 16, 2007
If Drugs are not Taken -
How Different Antipsychotics Influence Compliance of
Schizophrenic Patients
S. G. Schorr, J. R. B. J. Brouwers, K. Taxis
Fortschr
Neurol Psychiatr 2007; 75: 473-476
Olanzapine Versus Chlorpromazine in the Treatment of Schizophrenia: A
Pooled Analysis of Four 6-Week, Randomized, Open-Label Studies in the Middle
East and
Dossenbach, Martin; Treuer,
Tamas; Kryzhanovskaya, Ludmila; Saylan, Mete; Dominguez,
Svetlana; Huang, Xiaohong; On behalf of the HGCQ,
HGDQ, HGDT, and HGDV Study Team
Journal of Clinical
Psychopharmacology. 27(4):329-337,
August 2007
Metabolic
Impact of Switching Antipsychotic Therapy to Aripiprazole
After Weight Gain: A Pilot Study
Kim, Sun H; Ivanova, Oxana; Abbasi, Fahim A; Lamendola, Cindy A; Reaven, Gerald M; Glick, Ira D
Journal of Clinical
Psychopharmacology. 27(4):365-368,
August 2007
Early
Use of Clozapine for Poorly Responding First-Episode
Psychosis
Agid, Ofer;
Remington,
Journal of Clinical
Psychopharmacology. 27(4):369-373,
August 2007
Sex
Difference in Effects of Typical and Atypical Antipsychotics
on Glucose-Insulin Homeostasis and Lipid Metabolism in First-Episode
Schizophrenia
Wu, Ren-Rong; Zhao, Jing-Ping; Zhai, Jin-Guo; Guo, Xiao-Feng; Guo, Wen-Bin
Journal of Clinical Psychopharmacology.
27(4):374-379, August 2007
Outcome Following Clozapine Discontinuation: A Retrospective Analysis
James M. Atkinson, Petrina
Douglas-Hall, Catrin Fischetti,
Anna Sparshatt, and David M. Taylor
J Clin Psychiatry 2007;68:1027-1030
Efficacy of Piracetam in the Treatment of Tardive
Dyskinesia in Schizophrenic Patients: A Randomized,
Double-Blind, Placebo-Controlled Crossover Study
Igor Libov, Chanoch Miodownik, Yuly Bersudsky, Tzvi Dwolatzky, nd Vladimir Lerner
J Clin Psychiatry 2007;68:1031-1037
Metabolic Syndrome Among Persons With Schizophrenia and Other Psychotic
Disorders in a General Population Survey
Jaana M. Suvisaari,
Samuli I. Saarni, Jonna Perälä, Janne
V. J. Suvisaari, Tommi Härkänen, Jouko Lönnqvist, and Antti Reunanen
J Clin Psychiatry 2007;68:1045-1055
Oxidative–antioxidative systems and their relation with serum S100 B
levels in patients with schizophrenia: Effects of short term antipsychotic
treatment
Asli Sarandol, Selcuk Kirli, Cengiz Akkaya,
Aysun Altin, Meral Demirci and Emre Sarandol
Association between
major Multidrug Resistance 1 (MDR1) gene
polymorphisms and plasma concentration of prolactin
during risperidone treatment in schizophrenic
patients
Norio Yasui-Furukori, Shoko Tsuchimine,
Manabu Saito, Taku Nakagami,
Yasushi Sato and Sunao Kaneko
A review of liver
function tests during treatment with atypical antipsychotic drugs: A chart
review study
Nuray Atasoy, Ayten Erdogan,
Irem Yalug, Ulkem Ozturk, Numan
Konuk, Levent Atik and Yucel Ustundag
Clinical predictors
of therapeutic response to clozapine in a sample of
Turkish patients with treatment-resistant schizophrenia
Umit B. Semiz, Mesut Cetin, Cengiz Basoglu, Servet Ebrinc, Ozcan Uzun, Hasan
Herken, Hakan Balibey, Ayhan Algul and Alpay Ates
Statistical
validation of the criteria for symptom remission in schizophrenia: Preliminary
findings
Mark G. A. Opler, Lawrence H. Yang, Sue Caleo and Philip Alberti
BMC
Psychiatry
2007, 7:35
TEXTO GRATUITO
Predictors of
symptomatic remission in people with schizophrenia identified
Lambert M,
Schimmelmann BG, Naber D, et al.
Evidence-Based
Mental Health
2007;10:73
Haloperidol, risperidone and olanzapine are
similarly effective for first-episode non-affective psychosis but have
differing side effects
Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et
al.
Evidence-Based
Mental Health
2007;10:74
Haloperidol, olanzapine and risperidone reduce
treatment failure compared to aripiprazole, quetiapine and ziprasidone in
acute schizophrenia
McCue RE, Waheed
R, Urcuyo L, et
al.
Evidence-Based
Mental Health
2007;10:76
Head injury
slightly increases risk of non-affective psychosis but not schizophrenia
Evidence-Based
Mental Health
2007;10:92
Body
mass index and functioning in long-term schizophrenia.
Results of the DSP project
Raimo K.R. Salokangas, Teija Honkonen, Eija Stengård and Jarmo
Hietala
European
Psychiatry. Volume 22, Issue 5, July 2007, Pages 313-318
Sexual dysfunction
in patients with schizophrenia on antipsychotic medication
Alp Üçok, Cem İncesu,
Tamer Aker and Şahap Erkoç
European
Psychiatry. Volume 22, Issue 5, July 2007, Pages 328-333
Minimising
metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
A.H. Barnett, P. Mackin, I. Chaudhry,
A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler,
A. Rees, V. Singh, D. TayLor, J. Vora,
P.B. Jone
Journal of Psychopharmacology, Vol. 21, No. 4, 357-373
(2007)
The safety of quetiapine: results of a post-marketing surveillance study
on 1728 patients in England
Beverley R. Twaites, Lynda V. Wilton, Saad A. W. Shakir
Journal of Psychopharmacology, Vol. 21, No. 4, 392-399
(2007)
Alterations of
glucose metabolism during treatment with clozapine or
amisulpride: results from a prospective 16-week study
Maria A. Rettenbacher, Martina Hummer, Alex
Hofer, Susanne Baumgartner, Christoph Ebenbichler, Monika EdLinger,
Georg Kemmler, Monika Lechleitner,
W. Wolfgang Fleischhacker
Journal of Psychopharmacology, Vol. 21, No. 4, 400-404
(2007)
A 12-week,
double-blind, placebo-controlled trial of donepezil
as an adjunct to haloperidol for treating cognitive impairments in patients
with chronic schizophrenia
Bong-Ju Lee, Jung-Goo
Lee, Young-Hoon Kim
Journal of Psychopharmacology, Vol. 21, No. 4, 421-427
(2007)
Is clozapine—aripiprazole
combination a useful regime in the management of treatment-resistant
schizophrenia?
Kanapathippillai
Karunakaran, Tongeji E. Tungaraza, Giles C. Harborne
Journal of Psychopharmacology, Vol. 21, No. 4, 453-456
(2007)